Insomnia in bipolar patients. Bipolar disorder
Conditions
Interventions
Intervention 1: Intervention group: One 5 mg oral tablet of olanzapine, Sobhan Company. Orally at night before bedtime for 6 weeks to assess primary goals and then for 4 weeks to assess secondary goal
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 50 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Bipolar Disorder by Psychiatrist Based on DSM-5 and SCID Obtain informed consent from the patient or caretaker Age range 16-50 years. Note: this disease is more common in young people The presence of symptoms of insomnia in patients Patient has not taking psychiatric medication in the last 3 months
Exclusion criteria
Exclusion criteria: History of severe liver disease, heart disease, epilepsy, dementia; that can interfere with the safe administration of agomelatine or olanzapine Known severe allergic reactions or hypersensitivity to agomelatine, olanzapine or any excipients of these drugs Pregnancy or breastfeeding or planning to become pregnant during the study period, as these drugs may pose risks to the developing fetus Presence of prominent neurological or organic disorder Presence of simultaneous diagnosis of type one and two bipolar disorder Received ECT in the last 6 weeks Narcotic or opioid use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insomnia. Timepoint: The patients filled the ISI questionnaire before receiving the medicine, then two days after, and then weekly for 6 weeks or until discharge. Method of measurement: Insomnia Severity Index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaria Tavakoli Ardakani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed